Tenaya Therapeutics Reports Interim RIDGE‑1 Trial Data For TN‑401 Gene Therapy In PKP2‑Mutated ARVC

TN-401 was Well Tolerated at 3E13 vg/kg dose 

Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8

Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up

Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced interim data from the ongoing RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy for the potential treatment of adults with arrhythmogenic right ventricular cardiomyopathy (ARVC), a form of arrhythmogenic cardiomyopathy (ACM) that primarily impacts the right ventricle, caused by mutations in the plakophilin-2 gene, PKP2.

Data reported today include safety, biopsy and arrhythmia results from three patients who received TN-401 at a dose of 3E13 vg/kg. Patient follow-up at the time of data cut off ranged from 20-40 weeks post-dose. TN-401 was well tolerated, increased PKP2 protein expression from baseline in two of three patients and demonstrated evidence of meaningful improvements in arrhythmia burden as measured by premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs) for those patients with greater than six months follow up.